新型饮料粉补充剂对超重或肥胖成人体格测量指标、身体成分、代谢综合征组分及食欲的影响:一项随机临床试验方案
该随机三盲对照试验方案计划纳入72名超重或肥胖成人,干预组每日三次服用含巴氏灭活Akkermansia muciniphila、绿茶提取物和魔芋葡甘聚糖的2克饮料粉,对照组服用2克微晶纤维素,持续8周,评估体格测量、身体成分、代谢指标、血压和食欲。
要点
- 方案计划纳入72名超重或肥胖成人,随机分为干预组和对照组。
- 干预组每日三次服用含Akkermansia muciniphila、绿茶提取物和魔芋葡甘聚糖的2克饮料粉,持续8周。
- 对照组每日三次服用2克微晶纤维素,评估体格测量、身体成分、代谢指标、血压和食欲。
核心结论
- 该研究结果将为Akkermansia muciniphila联合益生元在肥胖及其相关代谢状态管理中的协同效应提供证据。
研究设计与样本
- 随机三盲对照临床试验方案,计划纳入72名超重或肥胖患者,随机分配至干预组或对照组。
关键数值与推荐
- 干预组每日三次服用2克含巴氏灭活Akkermansia muciniphila、绿茶提取物和魔芋葡甘聚糖的饮料粉,持续8周;对照组每日三次服用2克微晶纤维素,持续8周。
- 评估指标包括体格测量(体质指数、腰围和臀围)、身体成分(脂肪量、去脂体重、总体水等)、视觉模拟量表评估的食欲、血压以及生化参数包括空腹血糖(FBS)、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL)和高密度脂蛋白(HDL)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Overweight and obesity result from excessive fat accumulation and pose significant global health challenges linked to various diseases. Recent research suggests that gut microbiota, particularly dysbiosis, is vital in obesity development. Next-generation probiotics, especially Akkermansia muciniphila, alongside compounds found in green tea extract and konjac glucomannan, offer promise in obesity management by enhancing gut microbiota balance and metabolic function. This research investigates a unique supplement that integrates these elements, proposing that it will outperform lifestyle changes alone in improving anthropometric measures, body composition, metabolic metrics, blood pressure, and appetite among overweight or obese adults. METHODS: This study will include 72 overweight or obese patients, who will be randomly assigned to either the intervention or control group within a randomized, triple-blind controlled clinical trial. The intervention group will consume 2 g of beverage sachets containing pasteurized Akkermansia muciniphila, green tea extract, and konjac glucomannan three times daily. In comparison, the control group will take 2 g of microcrystalline cellulose three times daily for 8 weeks. Evaluations of anthropometry (body mass index, waist and hip circumference), body composition (fat mass, fat-free mass, total body water, etc.), appetite using a visual analogue scale, blood pressure, and biochemical parameters including fasting blood glucose (FBS), total cholesterol (TC), triglycerides (TG), low- and high-density lipoprotein (LDL and HDL) will be conducted. DISCUSSION: The results of this study will provide evidence for the synergistic effects of Akkermansia muciniphila combined with prebiotics in the management of obesity and its associated metabolic states. TRIAL REGISTRATION: Iranian Registry of Clinical Trials (IRCT20250222064807N2) (2025/03/26).
引用
- Asghari P, Afshari A, Sadeghi T, et al. The effects of a newly developed beverage powder supplement on anthropometric measures, body composition, metabolic syndrome components, and appetite in obese or overweight adults: a protocol for a randomized clinical trial study. Trials. 2025. PMID: 41163054. doi:10.1186/s13063-025-09180-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。